NCT03277573View on ClinicalTrials.gov

Salsalate in Patients Mild to Moderate Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

February 4, 2022

Study Completion Date

April 10, 2023

Conditions
Alzheimer Disease
Interventions
DRUG

Salsalate

Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.

DRUG

Placebo

Inactive ingredient

Trial Locations (2)

92093

University of California, San Diego, San Diego

94158

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Adam Boxer

OTHER

NCT03277573 - Salsalate in Patients Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter